Buchumschlag

Enhancing linkage to care for hepatitis B, D, and C patients: A retrospective‐prospective study

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Elena Vargas‐Accarino, Ariadna Rando‐Segura, Adriana Palom, Anna Feliu‐Prius, Joan Martínez‐Campreciós, Ana Barreira, Judit Romero‐Vico, Juan Carlos Ruiz‐Cobo, Jordi Llaneras, Mar Riveiro‐Barciela, Francisco Rodríguez‐Frías, Rafael Esteban, María Buti
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Letter: Why Assessment of ChILI Severity Accurately Matters?
von: Mar Riveiro‐Barciela, et al.
Veröffentlicht: (2024)

Baseline HDV ‐ RNA Levels Could Stratify Clinical Risk Before, But Not After, Cirrhosis in Chronic Hepatitis D: A Multicentre European Study
von: Adriana Palom, et al.
Veröffentlicht: (2026)

An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor‐induced liver injury
von: Mar Riveiro‐Barciela, et al.
Veröffentlicht: (2024)

Letter: “Tenofovir Alafenamide—The ‘Star of Potential’ for Long‐Term Chronic Hepatitis B Treatment. A Deep‐Dive Analysis of Phase 3 Clinical Trials.” Authors' Reply
von: Maria Buti
Veröffentlicht: (2025)

Enhancing Chronic Hepatitis B and D Management Through a Tailored Mobile Health Application: Real‐World Outcomes From the Adaptation of the NORA App
von: Judit Romero‐Vico, et al.
Veröffentlicht: (2026)

Letters on “Efficacy and Safety of Tenofovir Alafenamide ( TAF ) and Tenofovir Disoproxil Fumarate ( TDF ) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment.” Authors' Reply
von: Grace Lai‐Hung Wong, et al.
Veröffentlicht: (2025)

Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials
von: Maria Buti, et al.
Veröffentlicht: (2024)

Letter: Determining optimal ALT cut‐off values for predicting significant hepatic histological changes in chronic hepatitis B virus infection
von: Jianrong Li, et al.
Veröffentlicht: (2024)

Editorial: Can dietary gluten restriction improve hepatic steatosis?
von: Hariklia Kranidioti, et al.
Veröffentlicht: (2024)

Determining optimal ALT cut‐off values for predicting significant hepatic histological changes in patients with normal ALT in the grey zone of chronic hepatitis B virus infection
von: Na‐Ling Kang, et al.
Veröffentlicht: (2024)

Unveiling Drug‐Induced Autoimmune‐Like Hepatitis in Autoimmune Hepatitis Patients: A Multicenter Retrospective Study
von: Pinelopi Arvaniti, et al.
Veröffentlicht: (2025)

Letter: Association between chronic kidney disease, hepatitis B and antiviral treatments
von: Chen‐Pi Li, et al.
Veröffentlicht: (2024)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B
von: Jian Wang, et al.
Veröffentlicht: (2024)

Low socioeconomic status exacerbates unmet health‐related needs in patients with autoimmune hepatitis
von: Carolyn Singleton, et al.
Veröffentlicht: (2024)

Editorial: Viral hepatitis elimination: Still a big challenge: Care is not only for C
von: Nikolaos Papadopoulos, et al.
Veröffentlicht: (2024)

Review article: Contemporary management of gastrointestinal, pancreatic and hepatic toxicities of immune checkpoint inhibitors
von: Matthew J. Townsend, et al.
Veröffentlicht: (2024)

Development of hepatic fibrosis in common variable immunodeficiency‐related porto‐sinusoidal vascular disorder
von: Julian Hercun, et al.
Veröffentlicht: (2024)

Editorial: Solving the acute kidney injury puzzle in alcohol‐associated hepatitis—Challenges and insights
von: Vishnu Girish, et al.
Veröffentlicht: (2024)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B—Author's reply
von: Hyeyeon Hong, et al.
Veröffentlicht: (2024)

Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease
von: Nabil Noureddin, et al.
Veröffentlicht: (2024)

Letter: Use of liver stiffness measurement to identify liver cirrhosis in patients with chronic hepatitis D
von: Jian Wang, et al.
Veröffentlicht: (2024)

Outcomes of patients with alcohol‐associated hepatitis and acute kidney injury – Results from the HRS Harmony Consortium
von: Ann T. Ma, et al.
Veröffentlicht: (2024)

Insulin‐like growth factor‐1 in cirrhosis is linked to hepatic dysfunction and fibrogenesis and predicts liver‐related mortality
von: Lukas Hartl, et al.
Veröffentlicht: (2024)

Letter: Baseline age on antiviral treatment may significantly influence the clinical response of children with chronic hepatitis B
von: Jing Li, et al.
Veröffentlicht: (2024)

Letter: Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV—Authors' Reply
von: Juan Macias, et al.
Veröffentlicht: (2025)

Racial and ethnic disparities in untreated patients with hepatitis C virus‐related hepatocellular carcinoma but not in those with sustained virologic response
von: Jung Eun Park, et al.
Veröffentlicht: (2024)

CAMP‐B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance
von: Hye Won Lee, et al.
Veröffentlicht: (2024)

Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection
von: Lisa Sandmann, et al.
Veröffentlicht: (2024)

Efficacy and safety of filgotinib for ulcerative colitis: A real‐world multicenter retrospective study in Japan
von: Shintaro Akiyama, et al.
Veröffentlicht: (2024)

Editorial: How does the risk of hepatocellular carcinoma change over time in patients with a hepatitis C cure? Authors' reply
von: Philip Vutien, et al.
Veröffentlicht: (2024)

Letter: Baseline age on antiviral treatment may significantly influence the clinical response of children with chronic hepatitis B ‐ authors' reply
von: WenXian OuYang, et al.
Veröffentlicht: (2024)

The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes
von: Lana Bridi, et al.
Veröffentlicht: (2024)

A prospective study on the prevalence of at‐risk MASH in patients with type 2 diabetes mellitus in the United States
von: Nikita Mittal, et al.
Veröffentlicht: (2024)

Applying Lyon consensus criteria in the work‐up of patients with extra‐oesophageal symptoms – A multicentre retrospective study
von: Francesco Calabrese, et al.
Veröffentlicht: (2024)

Repeatability of vibration‐controlled transient elastography versus magnetic resonance elastography in patients with cirrhosis: A prospective study
von: Harris Siddiqi, et al.
Veröffentlicht: (2024)

Letter: Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B can increase body weight—Authors' reply
von: Eiichi Ogawa
Veröffentlicht: (2024)

Other causes of neurocognitive impairment than covert hepatic encephalopathy ( CHE ) are very frequent, either alone or associated with CHE , in cirrhotic patients with cognitive complaints
von: Philippe Sultanik, et al.
Veröffentlicht: (2024)

Letter: Association of persistently high HBsAg levels during HBeAg‐seropositive stage and hepatocellular carcinoma risk in chronic hepatitis B patients
von: Jian Wang, et al.
Veröffentlicht: (2024)

Prevalence and prognosis of patients with MASLD ‐related cirrhosis after an ICU hospitalization in France: A single‐centre prospective study
von: Philippe Sultanik, et al.
Veröffentlicht: (2024)

Quantitative MRCP and metrics of bile duct disease over time in patients with primary sclerosing cholangitis: A prospective study
von: Palak J. Trivedi, et al.
Veröffentlicht: (2024)